HOUSTON, Aug. 12, 2020 /PRNewswire/ -- The Mesothelioma Compensation Center says, "We are appealing to the wife or adult son-daughter of a waterworks worker or plumber who has just been diagnosed with mesothelioma anywhere in the nation to please call attorney Erik Karst of the law firm of Karst von Oiste at 800-714-0303. Erik Karst is one of the nation's leading mesothelioma attorneys and he and his amazing team at the law firm of Karst von Oiste will do everything possible to make certain you or your loved one gets properly compensated. A mesothelioma compensation claim for a person like this could exceed a million dollars. The average age for a person with mesothelioma in the US is about 72 years old.

"Attorney Erik Karst and his colleagues at the law firm of Karst von Oiste have been assisting plumbers, pipefitters and waterworks workers with mesothelioma for decades and they are responsible for over a billion dollars in financial compensation for people like this. For direct access to attorney Erik Karst of the law firm of Karst von Oiste please call 800-714-0303 anytime."www.karstvonoiste.com/

The biggest worry the Mesothelioma Compensation Center has for people with mesothelioma or their family is they get distracted by noise on the Internet about-no lawsuits needed, 'free' booklets, calculators, and other nonsense. First of all-mesothelioma compensation may or may not involve a lawsuit, and there is nothing 'free' on the Internet-just lawyers or law firms trying to identify people with mesothelioma. Why would a person with mesothelioma want to order a free book about a rare cancer they already know all about-because they have it?https://MesotheliomaCompensationCenter.Com

The Mesothelioma Compensation Center is focused on helping the following types of waterworks workers and plumbers-pipefitters who have mesothelioma:

For a listing of the nation's largest water/waste water public utility districts please refer to the following website:http://www.utilityconnection.com/page4s2.html

The Mesothelioma Compensation Center specializes in assisting specific types of people who have been diagnosed with mesothelioma. These people include the US Navy Veterans, oil refinery workers, power plant workers, boiler technicians, nuclear power plant workers, public utility workers, hydro-electric workers, chemical plant workers, plumbers, electricians, pipefitters, millwrights, welders, or oil and gas field workers. In most instances these people were exposed to asbestos in the 1950's, 1960's, 1970's, or 1980's.http://MesotheliomaCompensationCenter.Com

According to the CDC the states indicated with the highest incidence of mesothelioma include Maine, Massachusetts, Connecticut, Maryland, New Jersey, Pennsylvania, Ohio, West Virginia, Virginia, Michigan, Illinois, Minnesota, Louisiana, Washington, and Oregon.

However, a waterworks worker, a plumber or pipefitter with mesothelioma could live in any state including California, New York, Florida, Texas, Illinois, Ohio, Iowa, Indiana, Tennessee, North Carolina, Georgia, Nebraska, North Dakota, Wyoming, Colorado, New Mexico, Nevada, Utah, Arizona, Idaho, or Alaska.www.karstvonoiste.com/

For more information about asbestos exposure lung cancer and mesothelioma please visit the CDC's website on these topics:https://www.atsdr.cdc.gov/asbestos/health_effects_asbestos.html.

For more information about mesothelioma please refer to the National Institutes of Health's web site related to this rare form of cancer:https://www.cancer.gov/types/mesothelioma.

Media Contact:Michael Thomas800-714-0303[emailprotected]

SOURCE Mesothelioma Compensation Center

Link:

Mesothelioma Compensation Center Appeals to the Family of a Waterworks Worker or Plumber with Mesothelioma to Focus on Better Financial Compensation...

Published on August 11, 2020

Researchers from MedUniVienna have successfully identified a blockade of compounds that activate a rare mutation found in malignant mesothelioma cells, thus halting their unrestricted growth. This highly specific approach makes clear that the best way to treat this rare and fatal form of cancer is through a highly tailored approach.

The mesothelioma investigators focused on the impact that telomerase has on the growth and spread of cancer cells. Telomerase is an enzyme that is active in rapidly dividing cells in our bodies. Though it plays a positive role in most instances, it also facilitates many types of cancer growth and is found in excessive amounts in mesothelioma patients.

The researchers determined that a particularly aggressive subgroup of malignant pleural mesothelioma cells have a distinct genetic mutation that serves to promote the production of the TERT gene, which plays an outsized role in the activation of telomerase. Through this discovery, they were able to identify a new treatment strategy for those suffering from the rare form of cancer and who test positive for the mutation.

Writing in the journalClinical Cancer Research, the researchers explained that the mutation they identified is found in the regulatory region of the cancer cell, which determines how much of a protein is produced. Previous cancer studies have shown that mutations activating the TERT gene are found in families with high genetic tendencies towards cancer, and are associated with other highly aggressive tumors like melanoma and glioblastoma.

Though the TERT gene mutation is only present in a small subgroup of patients diagnosed with malignant pleural mesothelioma, those that have it generally have an extremely poor prognosis. The researchers found that by inhibiting a specific protein linked to the activation of the mutated TERT gene, they were able to block its aggressiveness. According to Walter Berger, Member, Comprehensive Cancer Center, Institute of Cancer Research, Medical University of Vienna, We are currently investigating whether a pharmacological blockade of the ETS factors has potential as a new treatment option for patients with TERT promoter-mutated MPM. If this proves to be the case, the mutation would be both a biomarker for the selection of suitable patients and a therapeutic target an ideal combination for precision medicine.

Every person diagnosed with malignant pleural mesothelioma has a different story of exposure and a different experience with the disease. The Patient Advocates at Mesothelioma.net are here to help you make sense of your situation. Contact us today at 1-800-692-8608.

Learn more about and contact Terri

Continued here:

Vienna Researchers' Mesothelioma Discovery Highlights Use of Precision Medicine - Mesothelioma.net Blog

HOUSTON, Aug. 11, 2020 /PRNewswire/ --The Mesothelioma Victims Center says, "We are open 24-7 to make certain a person with mesothelioma or their wife, and or adult son-daughter has resources and help. We are advocates for people with mesothelioma and there is not much we would not do to assist a family in this difficult situation. Unfortunately, we live in the age of the Coronavirus where we fear many people who have been diagnosed with mesothelioma have put their financial compensation on hold because they don't want to deal with lawyers-or because they are so sick they don't want to deal with compensation. If this sounds like you or your family member please feel free to call us anytime at 800-714-0303-we want to help.

"We are passionate advocates for people with mesothelioma and we want a person with this rare cancer to get the best possible financial compensation results-nationwide. To make certain the best possible compensation results happen we have endorsed attorney Erik Karst of the managing partner of the law firm of Karst von Oiste. Erik is one of the nation's leading mesothelioma attorneys. Erik Karst and his colleagues at the law firm of Karst von Oiste have been assisting people with mesothelioma for decades and they are responsible for over a billion dollars in compensation settlement results for people like this. For direct access to attorney Erik Karst of the law firm of Karst von Oiste please call 800-714-0303."www.karstvonoiste.com/

On a typical year between 2500 and 3000 US citizens will be diagnosed with mesothelioma. By comparison about 225,000 US citizens will be diagnosed with lung cancer. Unfortunately, because of the Coronavius the numbers of people who have mesothelioma or lung cancer will probably be dramatically reduced in 2020. Not because there are fewer people with these cancers-but because these people were misdiagnosed with the Coronavirus-COVID-19. "If you know your loved one had significant exposure to asbestos prior to 1982-and he is now in the hospital with suspected Coronavirus-please tell the physicians treating him about the asbestos exposure. Mesothelioma and the Coronavirus have similar symptoms. There is no compensation for the Coronavirus. Financial compensation for a person with mesothelioma might exceed a million dollars."https://MesotheliomaVictimsCenter.Com

Each year about 3000 US citizens will be diagnosed with mesothelioma. Mesothelioma is caused by exposure to asbestos. High -risk work groups for exposure to asbestos include US Navy Veterans, power plant workers, shipyard workers, oil refinery workers, steel mill workers, miners, manufacturing workers, pulp or paper mill workers, millwrights, welders, plumbers, electricians, auto mechanics, machinists, construction workers, rail road workers, and firemen. Typically, the exposure to asbestos for these types of workers occurred in the 1950's, 1960's, 1970's, or 1980's.https://MesotheliomaVictimsCenter.Com

According to the CDC the states indicated with the highest incidence of mesothelioma include Maine, Massachusetts, Connecticut, Maryland, New Jersey, Pennsylvania, Ohio, West Virginia, Virginia, Michigan, Illinois, Minnesota, Louisiana, Washington, and Oregon.

However, based on the calls the Mesothelioma Victims Center receives a person with confirmed mesothelioma could live in any state including New York, Florida, California, Texas, Illinois, Ohio, Iowa, Indiana, Missouri, North Carolina, Kentucky, Tennessee, Georgia, Alabama, Oklahoma, Arkansas, Kansas, Nebraska, North Dakota, Wyoming, Colorado, New Mexico, Utah, Nevada, Arizona, Idaho, or Alaska.www.karstvonoiste.com/

For more information about mesothelioma please refer to the National Institutes of Health's web site related to this rare form of cancer:https://www.cancer.gov/types/mesothelioma.

Media Contact:

Michael Thomas800-714-0303[emailprotected]

SOURCE Mesothelioma Victims Center

Mesothelioma Victims Center

See the original post here:

Mesothelioma Victims Center is Open 24-7 to Make Certain a Person with Confirmed Mesothelioma Receives the Best Compensation Results and They Endorse...

The research report on Malignant Mesothelioma market comprises of insights in terms of pivotal parameters such as production as well as the consumption patterns alongside revenue estimations for the projected timeframe. Speaking of production aspects, the study offers an in-depth analysis regarding the manufacturing processes along with the gross revenue amassed by the leading producers operating in this business arena. The core objective of the Malignant Mesothelioma market report is to help organizations gain aa better understanding of this business sphere in terms of the key growth drivers, restraints, and opportunities influencing the market dynamics.

According to the report, the market is projected to expand with a CAGR of XX% over the review period 2020-2025.

In the midst of the lockdown due to the COVID-19 pandemic, several industries have been forced to halt their operations which has dealt a major blow to their revenues. Some of them are projected to face challenges even after the economy recovers.

Request Sample Copy of this Report @ https://www.aeresearch.net/request-sample/269903

Majority of businesses have realigned their priorities and revised their budget to ensure profitability in the forthcoming years. Our all-inclusive analysis of this industry suggests reliable strategies to help you draft a strong action plan for the future.

Further, the research report forecasts revenues and assesses the trends of each sub-market to identify the prospects of this market.

Major highlights of the Malignant Mesothelioma market report:

Malignant Mesothelioma Market segments covered in the report:

Regional segmentation: North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India, Southeast Asia and Australia), South America (Brazil, Argentina, Colombia) and Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa).

Product categories:

Market share of each product type based on their sales and revenue.

Application spectrum:

Competitive outlook:

Basic company details, manufacturing sites, and competitors of each company

Highlights of the Report:

Request Customization on This Report @ https://www.aeresearch.net/request-for-customization/269903

View original post here:

Malignant Mesothelioma Market Overview, Major Manufacturers and Production Pric - News by aeresearch

By Hannah Albarazi

Law360 is providing free access to its coronavirus coverage to make sure all members of the legal community have accurate information in this time of uncertainty and change. Use the form below to sign up for any of our daily newsletters. Signing up for any of our section newsletters will opt you in to the daily Coronavirus briefing.

Law360, San Francisco (August 11, 2020, 6:05 PM EDT) -- A California judge declined Tuesday to postpone an impending San Francisco jury trial in an asbestos suit against Honeywell International and others, overruling defense attorneys' concerns that in-person trials amid the COVID-19 pandemic are unsafe and that remote jurors can be inattentive as they juggle home life and jury service.

Defense attorneys urged San Francisco Superior Court Judge Harold Kahn to suspend Gary and Karen Garrison's jury trial against more than a dozen companies over occupational exposure to asbestos until it is safe to hold it in person, spelling out for the judgethe potential problem of remote jurors multitasking during court proceedings.

Lindsay Weiss of Manning Gross & Massenburg LLP, counsel for defendant Temporary Plant Cleaners Inc., told the judge that not only is it dangerous for attorneys, the court staff, experts, witnesses and jurors to come into the courthouse as they did for Tuesday's hearing it's also not feasible to do the trial completely remotely.

She said across the San Francisco Bay, in Alameda County, jurors appearing remotely there have been seen working out, cooking and doing childcare during court proceedings. She said attentive jurors are a crucial part of a fair trial and that must not be compromised.

"I believe it is not a fair process," Weiss told the judge.

But Judge Kahn rejected the defendants' motion to continue the Garrisons' trial, saying he saw no other way to proceed except to start preparing for a jury trial.

Part of the urgency appears to be Gary Garrisons' health condition.

Gary and Karen Garrison filed suit in May 2019 alleging Gary suffered permanent injuries as a result of occupational exposure to asbestos fibers.

The defendants which include Honeywell, Scott Technologies, Goodyear and O'Reilly Auto Enterprises, among others intentionally concealed from the public the health risks posed by asbestos and were financially motivated to do so, the family alleges.

The companies negligently exposed Gary Garrison to asbestos causing him permanent injuries, according to the suit.

A rigorous review of the epidemiological data shows that all types of asbestos fibers are causally implicated in the development of various diseases and premature death, the Garrisons say, noting that since the 1960s the scientific evidence linking occupational and environmental asbestos exposure to lung cancer,asbestosis and mesothelioma has become "overwhelming."

The "mainstream scientific and medical community is in consensus that exposure to asbestos at current regulatory levels results in excess incidence of mesothelioma and that any occupational or para-occupational exposure to asbestos even that described as low-level or brief in duration must be regarded as causal in an individual with clinical mesothelioma," the Garrisons said in their complaint.

As a result of exposure to asbestos fibers, Gary Garrison says he has suffered lung cancer, pleural disease, asbestosis and lung damage, as well as emotional distress. He says the injuries have also left him with medical bills and loss of income.

The Garrisons are seeking punitive damages.

According to the Garrisons, the companies' conduct was "willful, malicious, fraudulent, outrageous and in conscious disregard and indifference" to the safety of those exposed.

On Tuesday, Judge Khan attempted to push forward with the trial logistics, working with the attorneys to come up with the best ways to carry out a jury trial in the time of COVID-19.

The parties did not immediately respond to requests for comment Tuesday.

The Garrisons are represented by Alan Richard Brayton and David R. Donadio of Brayton Purcell LLP.

Temporary Plant Cleaners is represented by Lindsay Weiss and Abigail P. Adams of Manning Gross & Massenburg LLP.

Scott Technologies Inc. is represented by Nicolas P. Martin and B. Gardiner Mckleroy of Wilson Elser Moskowitz Edelman & Dicker LLP.

Honeywell Technologies is represented by Alice Wong of McDermott Will & Emery LLP.

The case is Gary Garrison et al. v. Honeywell International Inc. et al., case number CGC19276790, in the Superior Court of California, County of San Francisco.

--Editing by Alyssa Miller.

For a reprint of this article, please contact reprints@law360.com.

Read the rest here:

Fears Of Virus And Distracted Jury Won't Stop Asbestos Trial - Law360

CheckMate 743 Shows That Dual Immunotherapy, Nivolumab + Ipilimumab, Improves Overall Survival for Patients with Previously Untreated Mesothelioma

DENVER, Aug. 08, 2020 (GLOBE NEWSWIRE) -- The combination of first-line nivolumab and ipilimumab demonstrated an improvement of overall survival for patients with unresectable malignant pleural mesothelioma compared to platinum-based chemotherapy.

The study is presented by Paul Baas, M.D., from The Netherlands Cancer Institute and The University of Leiden, in Amsterdam. Watch a video of Dr. Baas explaining his research here: https://vimeo.com/443190432/32a40271f0

Nivolumab is an immunotherapy that works as a checkpoint inhibitor, blocking a signal that prevents activation of T cells from attacking the cancer. Ipilimumab is a monoclonal antibody that works to activate the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system. When administered in combination, this dual immunotherapy has shown clinical benefit in 6 different tumor types, including mesothelioma.

In this large phase III study, Dr. Baas and the global study investigators randomly assigned more than 600 patients: 303 to the nivolumab + ipilimumab arm and 302 to the chemotherapy arm. The study had a minimal follow up of close to two years. Two-year overall survival rates were 40.8% for the patients in the experimental treatment arm vs 27.0% in chemotherapy arm. Of the 30.3% of patients in the study-combination group who experienced grade 3-4 adverse events, 15% discontinued therapy compared with 7.4% of the 32.0% of patients in chemotherapy group.

CheckMate 743 met its primary endpoint of statistically improved OS with nivolumab + ipilimumab vs standard of care chemotherapy in first-line treatment of patients with mesothelioma, said Dr. Baas. These clinically meaningful data represent the first positive phase 3 trial of immunotherapy in first-line MPM and should be considered as a new standard of care.

Phase 3 eXalt3 Study Shows Significantly Longer Progression-Free Survival in Patients with ALK+ Lung Cancer with Ensartinib Versus Crizotinib

Patients with non-small cell lung cancer (NSCLC) carrying anaplastic lymphoma kinase (ALK) gene alterations who received ensartinib experienced substantially longer progression-free survival than a matched group of patients who received crizotinib.

The results were presented today by Leora Horn, MD, Ingram Associate Professor of Cancer Research in the Division of Hematology/Oncology and director of the Thoracic Oncology Program at Vanderbilt-Ingram Cancer Center, Nashville, Tenn. View a video interview of Dr. Horn discussing the trial here: https://vimeo.com/444703327/6ad043dd00.

Ensartinib (X-396) is a novel next-generation ALK tyrosine kinase inhibitor (TKI). According to Dr. Horn, in Phase 1 and 2 studies, ensartinib showed promising activity in patients with ALK+ NSCLC who were ALK TKI treatment naive or received prior crizotinib or second-generation ALK TKIs, including strong activity in patients with brain metastases.

Crizotinib is an anti-cancer drug acting as an ALK, MET, and ROS1 inhibitor, approved for treatment of some subtypes of patients with NSCLC (including ALK+) in the United States and other countries worldwide.

Dr. Horn and her colleagues at the participating cancer centers randomized 290 patients with ALK+ NSCLC to either ensartinib or crizotinibthe prespecified intent to treat (ITT) population with locally determined ALK+ NSCLC. Patients were stratified by prior chemotherapy, Eastern Cooperative Oncology Group performance status, brain metastases, and geographic region. Baseline characteristics were well balanced between the two groups: median age was 54.1; 26% of patients had prior chemotherapy, and 36% of patients had baseline brain metastases (5% had prior brain radiotherapy). The modified ITT population (the prespecified patient population that was ALK+ as confirmed by central Abbott FISH test) included 247 patients, of which 121 received ensartinib and 126 received crizotinib.

At the July 1, 2020 data cutoff, based on a pre-planned interim analysis design (at 75% of progression-free survival events) treatment was ongoing in 64 ensartinib-treated patients (45%) and 25 crizotinib-treated patients (17%). There were 139 patients who experienced disease progression (as assessed by blinded independent review committee, BIRC) or death, which represented 73% of progression events in the ITT population and 119 BIRC-events or deaths (63%) in the mITT population.

According to Dr. Horn, the trials analysis demonstrated a statistically significant difference between patients who received ensartinib, with a median progression-free survival of 25.8 months compared with 12.7 months with crizotinib, with a median follow-up of 23.8 and 20.2 months, respectively (HR, 0.52; 95% CI, 0.36-0.75; P=.0003 by log-rank test). In the mITT population, the median progression-free survival has not been reached yet for the ensartinib arm vs. 12.7 months for the crizotinib arm (HR, 0.48; 95% CI, 0.32-0.71; P=.0002 by log-rank test).

The overall response rate was 75% versus 67% with crizotinib; among patients with measurable brain metastases, the BIRC-assessed intracranial overall response rate was 64% with ensartinib versus 21% with crizotinib.

The time-to-treatment-failure rate in the brain in patients with no baseline brain metastases was also significantly lower with ensartinib compared to crizotinib (4% vs 24% at 12 months).

In patients with ALK-positive NSCLC, ensartinib significantly prolonged progression-free survival over crizotinib with a favorable safety profile, representing a new option in the first-line setting, Dr. Horn concluded.

Addition of Sintilimab to Pemetrexed and Platinum Improved Progression-Free Survival in Patients with Nonsquamous Non-Small Cell Lung CancerResults of ORIENT-11 Presented at IASLC Virtual Presidential Symposium

The interim analysis of ORIENT-11, a phase III double-blind randomized trial has shown a nearly two-fold increase in progression-free survival with addition of sintilimab to chemotherapy in patients with advanced or metastatic non-squamous non-small cell lung cancer without EGFR or ALK genomic aberrations, according to research data presented today at the International Association for the Study of Lung Cancer Virtual Presidential Symposium.

The research findings are also published simultaneously in the Journal of Thoracic Oncology, the journal of the International Association for the Study of Lung Cancer.

Previously, sintilimab in combination with pemetrexed and a platinum-based chemotherapy had shown promising activity for nonsquamous non small cell lung cancer in a phase 1b study, according to Li Zhang, M.D., of Sun Yat-sen University Cancer Center, Guangzhou, China.

Dr. Zhang and investigators from centers in China enrolled 397 patients in the study. Of these, 266 and 131 patients were randomly assigned to the sintilimab combination and to placebo combination, respectively. Patients with all ranges of PD-L1 expression (by tumor proportion score, TPS) were included. The median progression free survival per was significantly improved in sintilimab-combination group compared to placebo combination group (8.9 vs. 5.0 months).

Dr. Zhang reported that sintilimab-combination group showed a nominally significant improvement of overall survival The overall response rate also was improved for the sintilimab-combination group (51.9% versus 29%). The safety signal for the sintilimab combination was similar to that found in other studies, but rates of occurrence of grade > 3 adverse events were slightly higher in the sintilimab-combination group (61.7% versus 58.8%).

This study demonstrated that the addition of sintilimab to chemotherapy significantly improved progression-free survival and a nominally improved overall survival, with an acceptable safety profile in [patients with] first-line non-squamous non small cell lung cancer, said Dr. Zhang. In this study, we collected tumor samples at baseline of treatment. So, our next work will focus on biomarker exploration. By RNA sequencing of tumor samples, we look forward to searching a potential biomarker which can predict the survival benefit from PD-1 combination with chemotherapy.

For more information, visit https://www.iaslc.org/Conferences-Events/Event-Details/iaslc-wclc-2020-singapore-virtual-presidential-symposium

Chris Martin CMartin@DavidJamesGroup.com | 630-670-2745

Read more:

Lung cancer researchers present new clinical trial data at International Association for the Study of Lung Cancer World Conference on Lung Cancer...

HOUSTON, Aug. 10, 2020 /PRNewswire/ -- The US Navy Veterans Lung Cancer Advocate says, "We are urging a Navy Veteran who now has lung cancer and who decades ago had significant exposure to asbestos on a navy ship, submarine or at a navy shipyard to pursue financial compensation and to please call the lawyers at the law firm of Karst von Oiste at 800-714-0303 to get the job done. Financial compensation for a person like this might exceed $100,000. If we are talking about a Navy Veteran who spent his career in the navy the compensation might be in the hundreds of thousands of dollars.

"Most Navy Veterans or people with lung cancer, who also had significant exposure to asbestos prior to 1982 are not aware the $30 billion dollar-asbestos trust funds were set up for them too. The typical person we are trying to identify is over 60 years old and it does not matter if they smoked cigarettes or not. If this sounds like your husband or your dad, please call the lawyers at Karst von Oiste at 800-714-0303 to discuss what might turn out to be significant financial compensation. This is worth your time and your dad could be in any state."www.karstvonoiste.com/

The lawyers at the law firm of Karst von Oiste have been assisting Navy Veterans and people with asbestos exposure lung cancer for decades and they are responsible for over a billion dollars in financial compensation for people like this. For direct access to the lawyers at the law firm of Karst von Oiste please call 800-714-0303.www.karstvonoiste.com/

High-risk workplaces for asbestos exposure include the US Navy, shipyards, power plants, public utilities, manufacturing factories, chemical plants, oil refineries, mines, smelters, pulp and paper mills, aerospace manufacturing facilities, offshore oil rigs, demolition construction work sites, railroads, automotive manufacturing facilities, or auto brake shops. With lung cancer caused by asbestos exposure the lung cancer may not show up until decades after the exposure.https://USNavyLungCancer.Com

According to the American Cancer Society for nonsmokers who have been exposed to asbestos in their workplace the risk of lung cancer is five times that of unexposed workers.https://www.cdc.gov/cancer/lung/statistics/index.htm.

States with the highest incidence of lung cancer include Kentucky, West Virginia, Maine, Tennessee, Mississippi, Ohio, Indiana, Louisiana, Arkansas, Missouri, North Carolina, Rhode Island, Alabama, and Delaware.

However, asbestos exposure lung cancer can happen in any state including California, New York, Texas, Florida, Massachusetts, Connecticut, Pennsylvania, New Jersey, Illinois, Wisconsin, Minnesota, Nebraska, New Mexico, North Dakota, Wyoming, Utah, Montana, Idaho, Arizona, Washington, Oregon or Alaska.www.karstvonoiste.com/

For more information about asbestos exposure lung cancer and mesothelioma please visit the CDC's website on these topics:https://www.atsdr.cdc.gov/asbestos/health_effects_asbestos.html.

Media Contact:Michael Thomas800-714-0303242060@email4pr.com

Read the original post:

US Navy Veterans Lung Cancer Advocate Urges a Navy Veteran with Lung Cancer Who Had Asbestos Exposure Decades Ago to Pursue Compensation That Might...

Global Malignant Mesothelioma Therapeutic Market Report, History and Forecast 2015-2026, Breakdown Data by Companies, Key Regions, Types and Application

In 2019, the global Malignant Mesothelioma Therapeutic Market size was US$ xx million and it is expected to reach US$ xx million by the end of 2026, with a CAGR of xx% during 2021-2026.

Malignant Mesothelioma Therapeutic Market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Malignant Mesothelioma Therapeutic Market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.The Report scope furnishes with vital statistics about the current market status and manufacturers. It analyzes the in-depth business by considering different aspects, direction for companies, and strategy in the industry.

After analyzing the report and all the aspects of the new investment projects, it is assessed the overall research and closure offered. The analysis of each segment in-detailed with various point views; that include the availability of data, facts, and figures, past performance, trends, and way of approaching in the market. The Malignant Mesothelioma Therapeutic Market report also covers the in-depth analysis of the market dynamics, price, and forecast parameters which also include the demand, profit margin, supply and cost for the industry.

The report additionally provides a pest analysis of all five along with the SWOT analysis for all companies profiled in the report. The report also consists of various company profiles and their key players; it also includes the competitive scenario, opportunities, and market of geographic regions. The regional outlook on the Malignant Mesothelioma Therapeutic Market covers areas such as Europe, Asia, China, India, North America, and the rest of the globe.

In-depth analysis of expansion and growth strategies obtained by Key players and their effect on competition market growth. The research report also provides precise information on your competitors and their planning. All of the above will help you to make a clear plan for top-line growth.

Get sample copy of thisreport @ https://www.lexisbusinessinsights.com/request-sample-145635

Top key players @ Eli Lilly, Teva, Sanofi, Bristol-Myers Squibb, Pfizer, Roche, Merck, Ono Pharmaceutical, Mylan, Fresenius Kabi, and Sun Pharmaceuticals.

The main goal for the dissemination of this information is to give a descriptive analysis of how the trends could potentially affect the upcoming future of Malignant Mesothelioma Therapeutic Market during the forecast period. This markets competitive manufactures and the upcoming manufactures are studied with their detailed research. Revenue, production, price, market share of these players is mentioned with precise information.

Global Malignant Mesothelioma Therapeutic Market: Regional Segment Analysis

This report provides pinpoint analysis for changing competitive dynamics. It offers a forward-looking perspective on different factors driving or limiting market growth. It provides a five-year forecast assessed on the basis of how they Malignant Mesothelioma Therapeutic Market is predicted to grow. It helps in understanding the key product segments and their future and helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments.

Key questions answered in the report include:

What will the market size and the growth rate be in 2026?

What are the key factors driving the Global Malignant Mesothelioma Therapeutic Market?

What are the key market trends impacting the growth of the Global Malignant Mesothelioma Therapeutic Market?

What are the challenges to market growth?

Who are the key vendors in the Global Malignant Mesothelioma Therapeutic Market?

What are the market opportunities and threats faced by the vendors in the Global Malignant Mesothelioma Therapeutic Market?

Trending factors influencing the market shares of the Americas, APAC, Europe, and MEA.

The report includes six parts, dealing with:

1.) Basic information;

2.) The Asia Malignant Mesothelioma Therapeutic Market;

3.) The North American Malignant Mesothelioma Therapeutic Market;

4.) The European Malignant Mesothelioma Therapeutic Market;

5.) Market entry and investment feasibility;

6.) The report conclusion.

All the research report is made by using two techniques that are Primary and secondary research. There are various dynamic features of the business, like client need and feedback from the customers. Before (company name) curate any report, it has studied in-depth from all dynamic aspects such as industrial structure, application, classification, and definition.

The report focuses on some very essential points and gives a piece of full information about Revenue, production, price, and market share.

Malignant Mesothelioma Therapeutic Market report will enlist all sections and research for each and every point without showing any indeterminate of the company.

Reasons for Buying this Report

This report provides pin-point analysis for changing competitive dynamics

It provides a forward looking perspective on different factors driving or restraining market growth

It provides a six-year forecast assessed on the basis of how the market is predicted to grow

It helps in understanding the key product segments and their future

It provides pin point analysis of changing competition dynamics and keeps you ahead of competitors

It helps in making informed business decisions by having complete insights of market and by making in-depth analysis of market segments

TABLE OF CONTENT:

1 Report Overview

2 Global Growth Trends

3 Market Share by Key Players

4 Breakdown Data by Type and Application

5 United States

6 Europe

7 China

8 Japan

9 Southeast Asia

10 India

11 Central & South America

12 International Players Profiles

13 Market Forecast 2019-2025

14 Analysts Viewpoints/Conclusions

15 Appendix

Get Complete Brochure @ https://www.lexisbusinessinsights.com/request-sample-145635

About Us:

Statistical surveying reports is a solitary goal for all the business, organization and nation reports. We highlight huge archive of most recent industry reports, driving and specialty organization profiles, and market measurements discharged by rumored private distributors and open associations. Statistical surveying Store is the far reaching gathering of market knowledge items and administrations accessible on air. We have statistical surveying reports from number of driving distributors and update our gathering day by day to furnish our customers with the moment online access to our database. With access to this database, our customers will have the option to profit by master bits of knowledge on worldwide businesses, items, and market patterns

Contact Us:

Lexis Business Insights

Aaryan

(Business Development Manager)

US: +1 210 907 4145

APAC: +91 9867799788

6851 N Loop

1604 W San Antonio,

TX 78249

[emailprotected]

http://www.lexisbusinessinsights.com

Visit link:

Globel Malignant Mesothelioma Therapeutic Market Size, Comprehensive Analysis, Development Strategy, Future Plans and Industry Growth with High CAGR...

Finding a mesothelioma lawyer can be complicated and troublesome for those diagnosed with this illness. Mesothelioma is a rare cancer caused by asbestos exposure and thousands have been affected by this disease over the past 5 decades world wide. Compared to the coronavirus, it is much more rare and seen mainly in individuals with work history around asbestos in some shape or form. Due to the illness being caused by workplace exposure, many have decided to hire attorneys to go after asbestos corporations who are responsible for their developing condition, thus, the mesothelioma lawyer was born. Here are a few tips to look for when searching for a mesothelioma lawyer https://www.gpwlaw-mi.com/.

1. Asbestos Product and Corporation Database: This is the single most important aspect about mesothelioma attorneys that sets them apart from all other forms of personal injury lawyers. An asbestos product and corporation database essentially refers to a collection of documents relevant to potential cases from asbestos corporations which can include but is not limited to depositions, invoices, product records, products sold, locations, and other key documents which outline how exactly a company is responsible for a victims exposure to begin with.

2. Experience: Experience is a critical aspect about looking for any attorney actually. This key piece is crucial as typically the more experience an attorney has under his or her belt, the more successful they will be in court. This is assuming that the second step follows closely behind this one.

3. Track Record in Court: A lawyers track record in court essentially refers to how many cases he or she has won or lost. Obviously, the more wins, the more likely said attorney will be able to achieve the same successful result for you or your loved ones case.

4. Care: Your attorney must care about you and your case deeply. They should not be caught up on how much they can make from a client and truly do the best they can for each and every client.

5. Notability: This is a unique, but not always necessary aspect of a mesothelioma lawyer. Your lawyers notability is essentially how well known they are in their specific area of litigation. Asbestos litigation has existed in the United States for over 5 decades. With this being said, there are plenty of notable and well recognized mesothelioma law firms across the United States. Notability does not necessarily mean TV advertisers, do not let that fool you. Notability truly refers to large lump sum wins for clients and a consistent practice history spread across many states successfully.

If you or a loved one is finding it difficult to search for a mesothelioma lawyer, one good option for them would be the attorneys at Goldberg, Persky & White P.C., their attorneys have fought hard for victims of asbestos exposure since 1976 and are continuing to do so even amidst the global coronavirus pandemic. As with any form of lawsuit, time is of the essence as each state has laws referred to as statute of limitations. Statute of limitations essentially refers to the time limit allowed to file a lawsuit after someone has been diagnosed with mesothelioma. On average this number fluctuates state to state, so speaking with an attorney sooner than later is always preferred. To add to this, a successful mesothelioma case may take over a year to fully settle with all relevant asbestos corporations due to how long it takes to gather, present, and hear back from relevant parties as well as court proceedings. If you or a loved one was recently diagnosed with mesothelioma, contacting a mesothelioma lawyer can be a life changing decision for them.

See the original post:

Mesothelioma Lawyer: 5 Things to Look for in 2020 - California Herald

MT. PLEASANT, S.C., Aug. 7, 2020 /PRNewswire/ --Motley Rice LLC is investigating whether certain officers and directors of World Acceptance Corp. (NASDAQ: WRLD) breached their fiduciary duties to shareholders. World Acceptance Corp. is a consumer loan company headquartered in Greenville, S.C.

On Aug. 6, 2020, World Acceptance Corp. agreed to pay $21.7 million to resolve claims by the U.S. Securities and Exchange Commission (SEC) that the company's former subsidiary in Mexico paid millions in bribes to that country's government and union officials.According to the SEC's order, "the tone at the top from [WRLD] management did not support robust internal audit and compliance functions, and undermined the effectiveness of those functions."

If you have information that is relevant to the investigation or you would like to discuss the allegations, you may contact Motley Rice securities fraud lawyers Gregg Levin, Joshua Littlejohn and William Norton by calling 1-800-768-4026 toll free, or by email.

About Motley Rice Motley Rice LLC is one of the nation's largest plaintiffs' litigation firms. With a tradition of representing those whose rights have been violated, Motley Rice attorneys gained recognition for their pioneering asbestos lawsuits, their work with the State Attorneys General in the landmark litigation against Big Tobacco, and their representation of 9/11 families in the ongoing lawsuit against terrorist financiers. The firm continues to handle complex litigation in numerous areas, including securities fraud; antitrust; consumer protection; mesothelioma; environmental contamination; prescription and over-the-counter drugs; other medical devices; human rights; aviation disasters; and wrongful death. Motley Rice, headquartered in Mt. Pleasant, S.C., has additional offices around the country, including in New York, New Jersey, and Washington, D.C. For more information, contact Motley Rice attorneys Gregg Levin(DC, MA, SC), Joshua Littlejohn(SC), or William Norton(MA, NY, SC) 1.800.768.4026 or visit http://www.motleyrice.com. Motley Rice LLC, a South Carolina Limited Liability Company, is engaged in the New Jersey practice of law through Motley Rice New Jersey LLC. Esther Berezofsky is the attorney responsible for New Jersey practice. Connect with us on Facebook, LinkedIn, Instagramand Twitter.

SOURCE Motley Rice LLC

http://www.motleyrice.com

Read the original:

Breach Of Duty Investigation: World Acceptance Corp. (Nasdaq: WRLD) - PRNewswire

Following the passing of his mother, a 25-year-old and his friend will be embarking on a 1,000 mile cycle tour through six countries in her memory.

Alec Payne and Josh Ayres, 33, will be setting off from North Pickenham on Tuesday, September 8, before travelling through the Netherlands, Germany, Luxembourg, Belgium and France in the space of 14 days.

They are raising funds for the Swaffham and Litcham Home Hospice who supported Alecs mother Sharon during her illness.

Sharon, a former nurse at the Queen Elizabeth Hospital and a prominent figure at Swaffham Cricket Club, died at the age of 50 after a long battle with cancer.

And Alec and Josh who met at the Anglia Ruskin University have already surpassed their fundraising target of 2,000 in aid of the hospice.

Alec said: We are quite overwhelmed by the support we have received so far from close family and friends. The idea came from Josh who had been doing quite a lot of biking during lockdown.

Initially he wanted a new challenge and he met me and suggested this bike idea then I messaged him a week later to say I would do it.

The friends have a backup plan if coronavirus travel restrictions get in the way of their fundraising challenge.

Plan B would see them cycle 1,000 miles within the UK instead.

A Just Giving page has been set up for the cause with a message from Alec stating: Swaffham and Litcham Home Hospice provides free care to patients who have cancer or terminal illnesses. Sadly, my mother, Sharon, passed away in April of this year after a long battle with cancer.

The Swaffham and Litcham Home Hospice provided her with incredible care during her illness.

2020 has seen Covid-19 affect many aspects of all our lives. Many services face uncertainty in these troubled times so we wanted to support the hospice so that they can continue giving invaluable care and support to their patients; just like they did with Sharon.

Sharon was described as the Mrs Cricket of Swaffham due to her dedication to the club which saw her take on a number of roles including child welfare officer, the fixtures secretary and the youth coordinator.

Both of her sons Alec and Jasper play for the club. Sharon had been diagnosed with Mesothelioma in 1998 and cruelly suffered a stroke the week before she passed away.

Josh, who lives in Lynn, said: I knew a lot about Sharon as Alec used to talk about her to me. When I found out I was completely gutted because we are pretty close friends.

Pam Tottle, complimentary therapist, who supported Sharon as one of the services provided by the Swaffham and Litcham Home Hospice, said: I met Sharon when she came to the Home Hospice for reflexology and reiki about five-years-ago.

"Over the years, we grew to trust each other with our most personal thoughts. Although Sharon was in constant pain, her goal was to watch her sons graduate from university. When Sharon put her mind to do something, she succeeded!

"My fondest memory of our sessions together were the big cwtchs (hugs) at the end. We would just hold each other and get the sense of giving and receiving whatever was needed at that time.

"Sharon was so very proud of her husband and sons bravery and compassion. She managed to stay with us long enough to know her boys were settled in their lives and would succeed in becoming good compassionate men.

A statement on behalf of the Home Hospice added: As an organisation it is a privilege to offer the services and support that we do. We enter the lives of those most vulnerable at a most difficult time.

"The bravery, courage and determination of those we support never ceases to amaze us and Sharon was certainly no exception, she was an inspiration to us all.

"We cannot thank both Alec and Josh enough for setting up this fantastic cycling challenge in order to raise much needed funds to help us to continue to provide our free services within the local community, providing practical and emotional support to those who have received a cancer diagnosis.

"The onset of Covid-19 has brought difficulties and challenges to all of us like we have never known before. In these exceptionally uncertain times as an organisation we need fundraising and donations more than ever. Every single penny donated counts.

"We wish Alec and Josh the very best of luck with their adventure and hope that as many people as possible support their amazing effort by way of donation on their Just Giving page.

The pair are offering a sponsorship for local businesses in which they pay a minimum of 100 in return for the business logo being printed on the cycling tops, as well as a plug on social media.

Contact Josh on 07828580210 if you are interested in sponsoring.

Their Just Giving page can be found at http://www.justgiving.com/fundraising/cycleforsharon

See original here:

Six-nation cycle challenge in memory of late mother and 'Mrs Cricket' of Swaffham - Lynn News

A mesothelioma clinical trial involving genetically modified T cells has opened to considerable acclaim, shrinking tumors in the first five patients who were treated.

The phase I portion of the clinical trial is designed to define the safety profile and optimal dosage level of TC-210, a novel immunotherapy targeting mesothelin, a cell-surface protein often overexpressed in several cancers.

While T cell modifications in the laboratory are proving safe and well tolerated, the initial signs of consistent efficacy became an early bonus in phase I.

Four of the patients treated had mesothelioma. The fifth had ovarian cancer. All five had previously undergone treatment that failed, including one targeting mesothelin.

Two of the five patients already had registered for hospice care before backtracking into the clinical trial.

What weve seen in the first few patients is very encouraging, Dr. Alfonso Quints-Cardama, chief medical officer at TCR2 Therapeutics, which is sponsoring the trial, told The Mesothelioma Center at Asbestos.com. Weve seen consistent benefits across the board. This early data is quite meaningful.

The study, which soon will move into phase II, is being conducted at five top cancer centers across the country. They are:

Its very early yet, but my hope is that what weve seen so far can be replicated in subsequent patients, Quints-Cardama said. I know people are paying all this attention to the efficacy weve seen, but the focus now is still on safety.

All five patients in the trial showed tumor regression with TC-210, including two with partial responses and two with stable disease through six months. The disease control rate among the five was 100%.

We could not be happier with our start of this clinical trial, Garry Menzel, president and chief executive officer at TCR2 Therapeutics, said during a recent presentation to investors. We are motivated by the desire to bring a truly novel therapy that can have a transformational impact for cancer patients.

The early success of this clinical trial has been especially notable because, until recently, T-cell therapy had not shown effectiveness with advanced-stage solid tumors, such as mesothelioma. Its success had been with blood cancers such as leukemia and lymphoma.

The U.S. Food and Drug Administration approved the first T-cell therapy for pediatric leukemia in 2017.

The early TC-210 data suggests our approach may overcome the challenges faced by many T-cell therapies in the hostile solid-tumor microenvironment, Quints-Cardama said.

T-cell therapy is based upon a patients unique genetic profile and a modification of their T cells, a type of white blood cell that is separated from the blood through a process known as leukapheresis.

This process can take up to four weeks before the T cells are reintroduced with an ability to identify and potentially eliminate tumor cells by targeting mesothelin.

Its like an engine with many different parts. Most of the T-cell therapies employ only one or two of those parts, Quints-Cardama said. We engage all of them. That makes a difference. Its much more complex, much more difficult to do.

The current clinical trial is also open to certain types of non-small cell lung cancer, ovarian cancer and cholangiocarcinoma. Individual levels of mesothelin expression must be satisfied to be eligible for the trial.

More patients beyond the first five already are enrolled and are being treated. Phase I patients are receiving a one-time infusion and are actively followed for six months.

Once a dosage level has been established phase II will begin, with each patient receiving first a preconditioning chemotherapy drug and then TC-210. A small number of patients also will be getting pembrolizumab (Keytruda), another immunotherapy drug with a different target, to look for possible synergy with TC-210.

A second infusion is possible if ordered by the study physician. For up to two years, patients will be asked to return regularly to the clinic. Blood samples will be taken approximately 30 times throughout the 24-month period.

Its a complex, complicated, laborious therapy, a completely new way of attacking these tumors, Quints-Cardama said. Were genetically reprograming a patients immune system to attack their cancer. And were seeing success.

TCR2 Therapeutics is a clinical-stage immunotherapy company based in Cambridge, Massachusetts, and focused on developing T-cell therapies for solid tumors and hematological malignancies.

Connect with a Mesothelioma DoctorFind a Top Specialist Near You

See the original post:

Mesothelioma T-Cell Therapy Shows Early Effectiveness in Trial - Asbestos.com

TCR2 Therapeutics announced on July 26 the first positive results for a new T-cell therapy to treat cancer patients, according to the press release on July 26th.

The first five patients treated in phase I of the clinical trial showed mesothelin-expressing tumor regression within six months of treatment. All patients received the same dose of TC-210 TRuC-T cell products. Four patients received lymphodepletion as well and one received TC-210 T cell products without lymphodepletion. Lymphodepletion is when lymphocytes (the cells that fight bacterial and viral infections) are destroyed. Only one patient experienced toxicity as a result of t-cell therapy.

The median reduction range for the sum of the diameters of target lesions was 42 percent.

Garry Menzel, President and Chief Executive Officer of TCR2 Therapeutics expressed gratitude for the results but mentioned that this is just the start of getting T-cell therapy approved for cancer patients.

We are delighted that our very first dose of TC-210 induced consistent tumor regression and clinical benefit in heavily pre-treated cancer patients, Menzel said. There are very few options for patients with solid tumors and those expressing mesothelin represent a significant frontier of unmet medical need. While these are early data requiring further study, we are encouraged by the potential of our TRuC-T cells as we continue to enroll and treat patients with the goal of quickly finding a recommended Phase 2 dose for TC-210.

Phase I of most clinical trials is mainly to assess the safety and efficacy of treatment before increasing dosage in patients. Phase two will use the dosage data from one and test the efficacy in tumor control and regression in about 50 patients, according to TCR2. Phase three is the stage where a treatment seeks approval from the Food and Drug Administration.

Patients in phase two will have a current diagnosis of non-small cell lung cancer, ovarian cancer, malignant pleural/peritoneal mesothelioma, or cholangiocarcinoma and all dosages will reflect the specific cancer type.

While more tests need to be run, Alfonso Quints-Cardama, M.D., Chief Medical Officer of TCR2 Therapeutics, said that this will bring some hope to cancer patients who have failed multiple lines of therapy.

Based on my prior experience working with both TCR-T and CAR-T cells, including the FDA approval of Kymriah, observing consistent clinical benefit in patients at presumably suboptimal T cell doses is quite meaningful, saidQuints-Cardama. These early TC-210 data suggest our approach may overcome the challenges faced by many T cell therapies in the hostile solid tumor microenvironment. Our enrolled patients have failed multiple lines of therapy, including standard chemotherapy, checkpoint inhibitors, and in some cases other mesothelin-directed approaches, in indications where survival has been historically shorter than six months.

According to clinicaltrials.gov, recruiting is still happening for this trial and people can still sign up for phase one.

T-cell therapy is still an emerging treatment for cancers such as mesothelioma. Chimeric antigen receptor T-cell therapy or CAR-T-cell therapy is the only other T-cell treatment that shows promising results. TRuC-T cells would add another form of treatment for mesothelioma, which normally has a poor prognosis.

TCR2 Therapeutics hosted a live webcast and conference call on July 27. The webcast can still be replayed on this webpage until approximately August 26.

For more information on mesothelioma treatment options, visit our webpage on treatments. If you have been diagnosed with mesothelioma or asbestos-related cancer, visit the contact page to talk to an advocate for compensation.

Continue reading here:

Emerging T-cell Therapy Treatment for Mesothelioma Shows Significant Tumor Reduction - MesoWatch

A new study shows that near-infrared phototherapy could be a promising treatment for individuals with pleural mesothelioma, according to a press release from Nagoya University.

The study, which tested mice and 12 human cell lines with malignant tumors, concluded that near-infrared photoimmunotherapy was a low-risk and effective method of killing cancer cells without harming surrounding cells due to the nature of near-infrared light, according to Kazuhide Sato, a researcher for the Institute for Advanced Research. There are several studies that suggest that near-infrared photoimmunotherapy is an effective cancer treatment, but little or no studies that focus on using this treatment for mesothelioma.

Malignant mesothelioma can be detected with high levels of podoplanin, a protein typically found in cancer cells. This type of treatment targets the expression of podoplanin. First, an anti-podoplanin antibody called NZ-1-IR700 was injected into the mice. This compound binds to podoplanin to both illuminate tumor cells and allow them to absorb light energy. This type of antibody is non-toxic to the body. When Satos team focused a near-infrared light into the chest cavity of mice, they saw the tumor cells rupture.

Sato suggested that further studies look into using a drainage device similar to the one used in patients to drain excess fluid in the lungs. The divide would help diffuse light directly into the chest cavity and cause more effective results.

One possible benefit of this treatment is that healthy cells are less likely to be destroyed. Sato acknowledged that NZ-1 would also bind to podoplanin on lymphatic epithelial cells, but he also suggested using CasMab, an antibody that detects the differences between cancer cells and healthy cells. With or without CasMab, the immunotherapy is regional and can help preserve the lungs. The anti-podoplanin antibodies are also not toxic to cells unless a near-infrared light is on them.

That being said, Sato said that there need to be more studies to ensure that the treatment will not unnecessarily harm the body. This study was partially performed on human cell lines with malignant tumors, but not on human beings.

Near-infrared photoimmunotherapy is a treatment that is perfect for patients with mesothelioma since it is usually localized to the lungs. Sato explained why this therapy works in the chest cavity.

"The lungs and chest cavity contain a large amount of air and are thus very good at effectively transmitting near-infrared light," says Sato. "NIR-PIT is a safe phototherapy option that can target a region of interest. The antibody-IR700 conjugate is also non-toxic to the body in the absence of near-infrared light irradiation. We thus thought that NIR-PIT could be an effective strategy for controlling localized MPM."

Currently, near-infrared photoimmunotherapy is in phase III clinical trials for head and neck cancer treatments for individuals who have failed at least two lines of therapy. The Food and Drug Administration has fast-tracked approval and this could be a possible treatment in the next few years, according to Sato.

Near-infrared light is not visible to the naked eye, but the wavelengths can penetrate the skin up to four inches. The body detects near-infrared light as heat. This type of light does not damage the skin as ultraviolet light would.

Mesothelioma is a rare type of cancer that affects the epithelial lining in the lungs, heart, and other organs. Typically mesothelioma is diagnosed in the late stage with very limited treatment options and a poor prognosis. Near-infrared photoimmunotherapy could bring hope to people with mesothelioma or their families.

For a full copy of the study, go to PubMed.

Read more from the original source:

Targeted phototherapy study Shows low-risk and effective treatment for Pleural Mesothelioma - MesoWatch

An analysis of mesothelioma patients who underwent cytoreductive surgery concludes that surgical treatment can improve the survival rate of a patient and should be the first choice for early treatment.

A study from the Annals of Surgical Oncology examined the survival rates of over 2000 peritoneal mesothelioma patients from 2003 to 2014. About 51% of patients did not have any kind of surgery to treat their cancer, while 34% received radical surgery according to the study. The patients who received surgery had an average survival rate of about 38.4 months compared to the non-surgery group which was 7.1 months.

Another group was made up of patients who received both radical surgery and chemotherapy. Those patients had a survival rate of about 41.8 months.

The results indicate a major improvement in prognosis. Before the year 2000, the average prognosis of patients with peritoneal mesothelioma was less than a year, according to the study.

The most recent study recommends that more doctors suggest surgery to a newly diagnosed patient to improve life-expectancy should he or she be fit enough to receive it.

Cytoreductive surgery is a lengthy process that involves surgeons inspecting each organ and removing any tumors. Generally, it is a curative treatment in the early stages of mesothelioma and palliative treatment in late stages to improve the quality of life in the terminal stage.

During some surgeries, treatment will also include hyperthermic intraperitoneal chemotherapy, a process where a doctor usually administers chemotherapy drugs directly into the peritoneum to kill cancer cells more. Using cytotoxic drugs post-operatively can prevent more tumors from forming afterward. Furthermore, the direct application of chemotherapy in high concentrations keeps systemic drug levels low, according to one study from the World Journal for Gastrointestinal Oncology.

Hyperthermic intraperitoneal chemotherapy cannot penetrate tumors deeply so surgery is the best preliminary treatment, according to the study.

Cytoreductive surgery can be beneficial for patients who are fit and are in the early stages of peritoneal mesothelioma due to the intensity of the surgery. The procedure lasts about ten hours.

This study referenced another analysis from 2015 where more than 1000 mesothelioma patients were analyzed for their survival rate after surgery and chemotherapy. The results predicted an improved survival rate of about five years and an additional five years if the patient received both surgery and chemotherapy.

According to the report, peritoneal mesothelioma makes up one-fourth of mesothelioma cases worldwide and difficult to detect early. Therefore, cytoreductive surgery is usually a form of palliative treatment. However, the 2015 study did mention that the increase in cytoreductive surgeries with chemotherapy have led to a more-improved prognosis.

If you think you may have been exposed to asbestos at any point in your lifetime, then it is important to get frequent checkups for mesothelioma. Catching peritoneal mesothelioma early can make a major difference in prognosis. You can also talk to someone about receiving compensation for the medical bills.

Peritoneal Mesothelioma is still a difficult form of cancer to treat, but cytoreductive surgery can improve the quality of life for many patients and result in a substantially longer prognosis.

Read the full study here.

See the original post:

New Study Shows that Surgery Can Improve Prognosis in Patients with Peritoneal Mesothelioma - MesoWatch

Published on August 03, 2020

Exposure to asbestos continues to wreak havoc on the lives of people around the world, causing malignant mesothelioma, lung cancer, asbestosis and other serious and fatal diseases. In the face of pressure from victims and asbestos companies alike, the U.S. Environmental Protection Agency is considering more than 75 comments regarding their Risk Evaluation for Asbestos. While health advocates are lobbying for an outright ban of the toxic substance, the chemical industry worries that the agency will shift its established threshold of danger, effectively eliminating their ability to defend against personal injury lawsuits.

While mesothelioma victims rightly want asbestos and asbestos-containing products entirely eliminated from the American landscape, those on the other side of the argument worry that the draft Risk Evaluation issued in March of 2020 would create new legal obligations for manufacturers and suppliers. These companies would have to report information about the hazards posed by their products.

Of even greater concern is the EPAs proposed lowering of the Inhalation Unit Risk (IUR) for chrysotile asbestos, a number which is often referenced by expert witnesses during mesothelioma litigation.Asbestos companies worry that a lowering would shift the perceived risk of different types of asbestos in the eyes of mesothelioma juries, making it more likely that victims will win their lawsuits.

The IUR is an estimate of cancer risk, i.e. the risk of being diagnosed with malignant mesothelioma, for someone who has a lifetime of exposure to asbestos. Asbestos manufacturers worry that the proposed IUR for chrysotile asbestos is contrary to their preferred position that chrysotile is less dangerous than amphibole asbestos. This would jeopardize their use of the chrysotile defense that says that it does not cause mesothelioma or that calculates the risk in a way that is contrary to asbestos victims claims of negligence.

Though the EPA has more than 75 comments to consider before releasing their final decision on asbestos, they have pledged to make their final decision by the end of 2020.

The EPAs decision is likely to have a significant impact on the risk of malignant mesothelioma and other asbestos-related diseases, as well as on legal issues involving asbestos. For more information, contact the Patient Advocates at Mesothelioma.net at 1-800-692-8608.

Learn more about and contact Terri

See more here:

Mesothelioma Victims and Asbestos Companies Watching EPA on Asbestos Decision - Mesothelioma.net Blog

An introduction to Malignant Mesothelioma Market Report

Marketo Graphics has released a new research report named as Malignant Mesothelioma Market 2020 to its extensive database. The report is inclusive of numerical data and certified data, which is gathered from certified sources and market experts. It includes and evaluates all the changes and shifts that are observed in the market and its supplementary markets. The provided information can, therefore, be used to improve and strengthen a firms standing in the Malignant Mesothelioma market.

This is the most recent report inclusive of the COVID-19 effects on the functioning of the market. It is well known that some changes, for the worse, were administered by the pandemic on all industries. The current scenario of the business sector and pandemics impact on the past and future of the industry are covered in this report.

This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering

AstraZeneca Plc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi, Eli Lilly and Company, Teva Pharmaceuticals, Boehringer Ingelheim GmbH, Mylan N.V., Fresenius Kabi AG, Sun Pharmaceuticals Industries Ltd, Corden Pharma International GmbH, Concordia International Corp, Kyowa Hakko Kirin Co Ltd., Polaris Pharmaceuticals, Inc., MolMed SpA, Ono Pharmaceutical Co. Ltd, Nichi-Iko Pharmaceutical Co., Ltd

Interested in this Malignant Mesothelioma market report? Get your FREE sample now! https://www.marketographics.com/sample-enquiry-form/11681

By Drug TypePemetrexed, Cisplatin, Carboplatin, Gemcitabine, Vinorelbine, Others

By AdministrationOral, Parenteral

By Distribution ChannelHospital Pharmacies, Retail Pharmacies, Oncology Centers

Estimating the potential size of the Malignant Mesothelioma industry

Industry experts conducting the study further estimate the potential of the Malignant Mesothelioma industry. Such information is important for firms looking to launch an innovative service or product on the market. Industry experts have measured the total volume of the given market. Researchers have calculated the industry in terms of sales by the competitors and end-user customers. Data on the entire size of the Malignant Mesothelioma market for a particular product or a service for the forecast period, 2019 to 2026 covered in the report makes it valuable. This information reveals the upper limit of the Malignant Mesothelioma industry for a specific product or service.

!!! Limited Time DISCOUNT Available!!! Get Your Copy at Discounted [emailprotected] https://www.marketographics.com/discount-enquiry-form/11681

Knowing the trends influencing the industry performance

Stakeholders, marketing executives and business owners planning to refer a market research report can use this study to design their offerings and understand how competitors attract their potential customers and manage their supply and distribution channels. When tracking the trends researchers have made a conscious effort to analyze and interpret the consumer behaviour. Besides, the research helps product owners to understand the changes in culture, target market as well as brands so they can draw the attention of the potential customers more effectively.

Geographically, this report studies the key regions, focuses on product sales, value, market share and growth opportunity in these regions, covering:

United States

Europe

China

Japan

Southeast Asia

India

Browse complete Malignant Mesothelioma report description And Full TOC @ https://www.marketographics.com/industry-reports/malignant-mesothelioma-market

There are many questions the research attempts to answer:

Why Choose Marketo Graphics?

Order Your Copy Now (Customized report delivered as per your specific requirement) @ https://www.marketographics.com/checkout-form11681

To summarize, the global Malignant Mesothelioma market report studies the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and the trends observed in the market that can either propel or curtail the growth rate of the industry. The market factors impacting the global sector also include provincial trade policies, international trade disputes, entry barriers, and other regulatory restrictions.

About Us:With reports from over 500 prominent publishers as well as daily updates on our collection, intended to empower companies and individuals catch-up with vital insights on industries operating across different geographies, along with the trends, share, size and growth rate of market verticals and numerous other services, we have our fingers dipped in just about everything market research-related. Besides meticulously curated research reports, our clients can also access our specialized services without any additional charges to gain vital market insights.

Contact Us:John WatsonHead of Business DevelopmentOffice No, 203 Chandan Nagar,Kharadi Pune, Maharashtra 411014Direct Line:+918484002482Visit our News Site:http://newssucceed.com

David is an Experience Business writer who regularly contributes to the blog, He specializes in manufacturing news

Originally posted here:

Impact of Covid-19 on Malignant Mesothelioma Market Market to Witness High Demand During 2020-2027 - Levee Report

An introduction to Malignant Mesothelioma Market Report

Marketo Graphics has released a new research report named as Malignant Mesothelioma Market 2020 to its extensive database. The report is inclusive of numerical data and certified data, which is gathered from certified sources and market experts. It includes and evaluates all the changes and shifts that are observed in the market and its supplementary markets. The provided information can, therefore, be used to improve and strengthen a firms standing in the Malignant Mesothelioma market.

This is the most recent report inclusive of the COVID-19 effects on the functioning of the market. It is well known that some changes, for the worse, were administered by the pandemic on all industries. The current scenario of the business sector and pandemics impact on the past and future of the industry are covered in this report.

This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering

AstraZeneca Plc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi, Eli Lilly and Company, Teva Pharmaceuticals, Boehringer Ingelheim GmbH, Mylan N.V., Fresenius Kabi AG, Sun Pharmaceuticals Industries Ltd, Corden Pharma International GmbH, Concordia International Corp, Kyowa Hakko Kirin Co Ltd., Polaris Pharmaceuticals, Inc., MolMed SpA, Ono Pharmaceutical Co. Ltd, Nichi-Iko Pharmaceutical Co., Ltd

Interested in this Malignant Mesothelioma market report? Get your FREE sample now! https://www.marketographics.com/sample-enquiry-form/11681

By Drug TypePemetrexed, Cisplatin, Carboplatin, Gemcitabine, Vinorelbine, Others

By AdministrationOral, Parenteral

By Distribution ChannelHospital Pharmacies, Retail Pharmacies, Oncology Centers

Estimating the potential size of the Malignant Mesothelioma industry

Industry experts conducting the study further estimate the potential of the Malignant Mesothelioma industry. Such information is important for firms looking to launch an innovative service or product on the market. Industry experts have measured the total volume of the given market. Researchers have calculated the industry in terms of sales by the competitors and end-user customers. Data on the entire size of the Malignant Mesothelioma market for a particular product or a service for the forecast period, 2019 to 2026 covered in the report makes it valuable. This information reveals the upper limit of the Malignant Mesothelioma industry for a specific product or service.

!!! Limited Time DISCOUNT Available!!! Get Your Copy at Discounted [emailprotected] https://www.marketographics.com/discount-enquiry-form/11681

Knowing the trends influencing the industry performance

Stakeholders, marketing executives and business owners planning to refer a market research report can use this study to design their offerings and understand how competitors attract their potential customers and manage their supply and distribution channels. When tracking the trends researchers have made a conscious effort to analyze and interpret the consumer behaviour. Besides, the research helps product owners to understand the changes in culture, target market as well as brands so they can draw the attention of the potential customers more effectively.

Geographically, this report studies the key regions, focuses on product sales, value, market share and growth opportunity in these regions, covering:

United States

Europe

China

Japan

Southeast Asia

India

Browse complete Malignant Mesothelioma report description And Full TOC @ https://www.marketographics.com/industry-reports/malignant-mesothelioma-market

There are many questions the research attempts to answer:

Why Choose Marketo Graphics?

Order Your Copy Now (Customized report delivered as per your specific requirement) @ https://www.marketographics.com/checkout-form11681

To summarize, the global Malignant Mesothelioma market report studies the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and the trends observed in the market that can either propel or curtail the growth rate of the industry. The market factors impacting the global sector also include provincial trade policies, international trade disputes, entry barriers, and other regulatory restrictions.

About Us:With reports from over 500 prominent publishers as well as daily updates on our collection, intended to empower companies and individuals catch-up with vital insights on industries operating across different geographies, along with the trends, share, size and growth rate of market verticals and numerous other services, we have our fingers dipped in just about everything market research-related. Besides meticulously curated research reports, our clients can also access our specialized services without any additional charges to gain vital market insights.

Contact Us:John WatsonHead of Business DevelopmentOffice No, 203 Chandan Nagar,Kharadi Pune, Maharashtra 411014Direct Line:+918484002482Visit our News Site:http://newssucceed.com

Original post:

Impact of Covid-19 on Malignant Mesothelioma Market to Witness High Demand During 2020-2027 - Research Newspaper

AN ENGINEER spent his working life surrounded by deadly asbestos, often with no protective equipment, an inquest has heard.

Roy Gee-Clough died at home on May 6 from mesothelioma, a cancer of the lungs caused by inhaling asbestos fibres.

Assistant coroner Catherine Cundy was told how, before his death, 77-year-old Mr Gee-Clough had made a statement outlining his working conditions at the British Rail Loco Works and then BAe Systems, where the air was sometimes so thick with a material containing asbestos that work had to stop.

Mr Gee-Clough, a married father, told how he began working at the Horwich Loco Works as a 14-year-old office boy in 1957, delivering post to all the departments, before beginning his five year apprenticeship and working in the erecting shop where he had the job of lagging boilers with asbestos mattresses.

"During that job dust was created and it covered his boiler suit," said Ms Cundy. "The air was generally thick with asbestos dust. There were no masks or protection provided."

In 1964 he moved to British Aerospace at Lostock where he spent the rest of his career making components for missiles.

In his early 30s he was given the task of machining a component for the Sea Slug missile, which involved using Dursetos, an asbestos sheet material.

"He says there was a phenomenal amount of dust which came off the machines that was processing the Durestos and every so often it was too much to cope with and so the work would have to stop for a while while things cleared," said Ms Cundy.

A colleague working next to Mr Gee-Clough died from mesothelioma but he remained apparently healthy after retiring, aged 48, when he was made redundant.

He and his wife Gillian divided their time between their homes in Spain and Stocks Park Drive, Horwich and his step-daughter, Deborah Arstall, described how he was artistic and a keen walker.

But in June 2018, before he and his wife were due to head back to Spain, he paid a visit to the doctor after noticing a shortness of breath.

Mesothelioma, which can take 30 or more years to show symptoms, was diagnosed and Mr Gee-Clough underwent several courses of chemotherapy and palliative radiotheraphy before his condition deteriorated in Spring this year and he died.

Ms Cundy recorded a conclusion that Mr Gee-Clough died as a result of industrial disease. None of his family were at the inquest so she asked that her condolences be passed to them.

Read more from the original source:

Asbestos tragedy of worker covered in dust - The Bolton News

AN ENGINEER spent his working life surrounded by deadly asbestos, often with no protective equipment, an inquest has heard.

Roy Gee-Clough died at home on May 6 from mesothelioma, a cancer of the lungs caused by inhaling asbestos fibres.

Assistant coroner Catherine Cundy was told how, before his death, 77-year-old Mr Gee-Clough had made a statement outlining his working conditions at the British Rail Loco Works and then BAe Systems, where the air was sometimes so thick with a material containing asbestos that work had to stop.

Mr Gee-Clough, a married father, told how he began working at the Horwich Loco Works as a 14-year-old office boy in 1957, delivering post to all the departments, before beginning his five year apprenticeship and working in the erecting shop where he had the job of lagging boilers with asbestos mattresses.

"During that job dust was created and it covered his boiler suit," said Ms Cundy. "The air was generally thick with asbestos dust. There were no masks or protection provided."

In 1964 he moved to British Aerospace at Lostock where he spent the rest of his career making components for missiles.

In his early 30s he was given the task of machining a component for the Sea Slug missile, which involved using Dursetos, an asbestos sheet material.

"He says there was a phenomenal amount of dust which came off the machines that was processing the Durestos and every so often it was too much to cope with and so the work would have to stop for a while while things cleared," said Ms Cundy.

A colleague working next to Mr Gee-Clough died from mesothelioma but he remained apparently healthy after retiring, aged 48, when he was made redundant.

He and his wife Gillian divided their time between their homes in Spain and Stocks Park Drive, Horwich and his step-daughter, Deborah Arstall, described how he was artistic and a keen walker.

But in June 2018, before he and his wife were due to head back to Spain, he paid a visit to the doctor after noticing a shortness of breath.

Mesothelioma, which can take 30 or more years to show symptoms, was diagnosed and Mr Gee-Clough underwent several courses of chemotherapy and palliative radiotheraphy before his condition deteriorated in Spring this year and he died.

Ms Cundy recorded a conclusion that Mr Gee-Clough died as a result of industrial disease. None of his family were at the inquest so she asked that her condolences be passed to them.

Go here to read the rest:

Asbestos tragedy of worker covered in dust - This Is Lancashire